SI2575884T1 - Uporabe in sestavki za zdravljenje supurativnega hidradenitisa (HS) - Google Patents

Uporabe in sestavki za zdravljenje supurativnega hidradenitisa (HS)

Info

Publication number
SI2575884T1
SI2575884T1 SI201131570T SI201131570T SI2575884T1 SI 2575884 T1 SI2575884 T1 SI 2575884T1 SI 201131570 T SI201131570 T SI 201131570T SI 201131570 T SI201131570 T SI 201131570T SI 2575884 T1 SI2575884 T1 SI 2575884T1
Authority
SI
Slovenia
Prior art keywords
compositions
treatment
hidradenitis suppurativa
suppurativa
hidradenitis
Prior art date
Application number
SI201131570T
Other languages
English (en)
Slovenian (sl)
Inventor
Martin M. Okun
Thomas C. Harris
Original Assignee
Abbvie Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45064648&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2575884(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Biotechnology Ltd filed Critical Abbvie Biotechnology Ltd
Publication of SI2575884T1 publication Critical patent/SI2575884T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
SI201131570T 2010-06-03 2011-06-03 Uporabe in sestavki za zdravljenje supurativnega hidradenitisa (HS) SI2575884T1 (sl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US35112510P 2010-06-03 2010-06-03
US201161430645P 2011-01-07 2011-01-07
US201161474764P 2011-04-13 2011-04-13
PCT/US2011/039135 WO2011153477A2 (en) 2010-06-03 2011-06-03 Uses and compositions for treatment of hidradenitis suppurativa (hs)
EP11790495.3A EP2575884B1 (en) 2010-06-03 2011-06-03 Uses and compositions for treatment of hidradenitis suppurativa (hs)

Publications (1)

Publication Number Publication Date
SI2575884T1 true SI2575884T1 (sl) 2018-10-30

Family

ID=45064648

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201131570T SI2575884T1 (sl) 2010-06-03 2011-06-03 Uporabe in sestavki za zdravljenje supurativnega hidradenitisa (HS)

Country Status (18)

Country Link
US (3) US8747854B2 (enExample)
EP (1) EP2575884B1 (enExample)
JP (2) JP5944382B2 (enExample)
CN (2) CN103079594B (enExample)
CA (1) CA2801917C (enExample)
CY (1) CY1120664T1 (enExample)
DK (1) DK2575884T3 (enExample)
ES (1) ES2685607T3 (enExample)
HR (1) HRP20181598T1 (enExample)
HU (1) HUE039740T2 (enExample)
LT (1) LT2575884T (enExample)
MX (1) MX2012014080A (enExample)
PL (1) PL2575884T3 (enExample)
PT (1) PT2575884T (enExample)
RS (1) RS57543B1 (enExample)
SI (1) SI2575884T1 (enExample)
SM (1) SMT201800428T1 (enExample)
WO (1) WO2011153477A2 (enExample)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
ATE239041T1 (de) 1996-02-09 2003-05-15 Basf Ag Humane antikörper welche an humanen tnfalpha binden
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20090280065A1 (en) * 2006-04-10 2009-11-12 Willian Mary K Uses and Compositions for Treatment of Psoriasis
TWI439284B (zh) 2004-04-09 2014-06-01 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
GB0414054D0 (en) 2004-06-23 2004-07-28 Owen Mumford Ltd Improvements relating to automatic injection devices
JP5757495B2 (ja) 2005-05-16 2015-07-29 アッヴィ バイオテクノロジー リミテッド びらん性多発性関節炎の治療のためのｔｎｆ阻害剤の使用
TW201337266A (zh) 2005-11-01 2013-09-16 Abbott Biotech Ltd 利用生物標記診斷關節黏連脊椎炎之方法及組合物
CN102391358B (zh) 2006-04-05 2016-08-10 艾伯维生物技术有限公司 抗体纯化
WO2007120626A2 (en) 2006-04-10 2007-10-25 Abbott Biotechnology Ltd. Uses and compositions for treatment of ankylosing spondylitis
US9605064B2 (en) * 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US9399061B2 (en) * 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
US20100021451A1 (en) 2006-06-08 2010-01-28 Wong Robert L Uses and compositions for treatment of ankylosing spondylitis
CN103316402A (zh) 2006-06-30 2013-09-25 艾伯维生物技术有限公司 自动注射装置
EP2684895A1 (en) 2006-10-27 2014-01-15 AbbVie Biotechnology Ltd Crystalline anti-hTNFalpha antibodies
EP2171451A4 (en) * 2007-06-11 2011-12-07 Abbott Biotech Ltd METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS
CA2693771A1 (en) * 2007-07-13 2009-01-22 Abbott Biotechnology Ltd. Methods and compositions for pulmonary administration of a tnf.alpha. inhibitor
MX2010001488A (es) * 2007-08-08 2010-03-01 Abbott Lab Composiciones y metodos para cristalizar anticuerpos.
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
US8420081B2 (en) * 2007-11-30 2013-04-16 Abbvie, Inc. Antibody formulations and methods of making same
MX2012014080A (es) * 2010-06-03 2013-05-01 Abbvie Biotechnology Ltd Usos y composiciones para el tratamiento de hidradenitis superativa (hs).
CN102946904A (zh) 2010-06-18 2013-02-27 埃克斯生物科技公司 关节炎治疗
PH12013500316A1 (en) 2010-08-23 2016-09-02 Janssen Biotech Inc Treatment for neoplastic diseases
TWI603739B (zh) 2010-11-11 2017-11-01 艾伯維生物技術有限責任公司 具有增進高濃度之抗－ＴＮＦα抗體之液體調配物
SG192119A1 (en) 2011-01-24 2013-08-30 Abbvie Biotechnology Ltd Automatic injection devices having overmolded gripping surfaces
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
HK1211981A1 (en) 2012-09-02 2016-06-03 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US9844594B2 (en) 2012-12-18 2017-12-19 Merck Sharp & Dohme Corp. Liquid formulations for an anti-TNF α antibody
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
AU2014337263B2 (en) 2013-10-16 2019-12-12 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
EP3247718B1 (en) 2015-01-21 2021-09-01 Outlook Therapeutics, Inc. Modulation of charge variants in a monoclonal antibody composition
EP3078675A1 (en) 2015-04-10 2016-10-12 Ares Trading S.A. Induction dosing regimen for the treatment of tnf alpha mediated disorders
EP3411401A1 (en) 2016-02-03 2018-12-12 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
RS62040B1 (sr) 2016-06-02 2021-07-30 Abbvie Inc Agonist receptora glukokortikoida i njegovi imunokonjugati
DK3538118T3 (da) 2016-11-11 2021-05-25 Sjaellands Univ Dermatologisk Afdeling Levende saprofytbakterier til anvendelse til behandling af hidradenitis suppurativa
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
JP7145162B2 (ja) 2017-02-16 2022-09-30 ヤンセン バイオテク，インコーポレイテッド 化膿性汗腺炎の処置
US20200277369A1 (en) * 2017-11-20 2020-09-03 Novartis Ag Method of treating hidradentitis suppurativa with il-17 antagonists
EP3658192B1 (en) 2017-12-01 2021-04-28 AbbVie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
WO2019130215A1 (en) * 2017-12-27 2019-07-04 To Pharmaceuticals Llc Cannabis compositions for the treatment of inflammatory skin disorders
AU2019236105B2 (en) 2018-03-14 2025-07-31 Boehringer Ingelheim International Gmbh Use of anti-IL-36R antibodies for treatment of generalized pustular psoriasis
TWI737000B (zh) * 2018-10-22 2021-08-21 美商美國禮來大藥廠 用於治療化膿性汗腺炎之泛-ｅｌｒ＋ｃｘｃ趨化介素抗體
TW202031265A (zh) 2018-11-15 2020-09-01 美商艾伯維有限公司 用於皮下投藥之醫藥調配物
AU2019389174A1 (en) 2018-11-30 2021-07-01 Kymera Therapeutics, Inc. Irak degraders and uses thereof
PH12022500002A1 (en) 2019-06-28 2023-04-03 Kymera Therapeutics Inc Irak degraders and uses thereof
US12558427B2 (en) 2019-07-17 2026-02-24 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
WO2021119159A1 (en) 2019-12-10 2021-06-17 Kymera Therapeutics, Inc. Irak degraders and uses thereof
CA3161878A1 (en) 2019-12-17 2021-06-24 Matthew M. Weiss Irak degraders and uses thereof
EP4167728A4 (en) * 2020-06-17 2024-09-04 Kymera Therapeutics, Inc. Irak degraders and uses thereof
MX2023000763A (es) 2020-07-17 2023-02-13 Boehringer Ingelheim Int Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrofilas.
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
AR124547A1 (es) 2020-12-30 2023-04-05 Kymera Therapeutics Inc Degradadores de irak y sus usos
MX2023009178A (es) 2021-02-15 2023-08-21 Kymera Therapeutics Inc Degradadores de la cinasa 4 asociada al receptor de interleucina 1 (irak4) y usos de los mismos.
EP4305207A2 (en) 2021-03-12 2024-01-17 Boehringer Ingelheim International GmbH Biomarkers associated with anti-il-36r antibody treatment in generalized pustular psoriasis
WO2022269451A1 (en) * 2021-06-22 2022-12-29 Novartis Ag Bispecific antibodies for use in treatment of hidradenitis suppurativa
JP2024540080A (ja) 2021-10-29 2024-10-31 カイメラ セラピューティクス， インコーポレイテッド Ｉｒａｋ４分解剤およびその合成
EP4472967A4 (en) 2022-01-31 2026-04-15 Kymera Therapeutics Inc Iraqi Degradation Agents and Their Uses
KR20250031013A (ko) * 2023-08-23 2025-03-06 (주)셀트리온 TNFα 관련 질환을 치료하는 방법
IL328258A (en) * 2024-01-03 2026-07-01 Abbvie Inc Luticizumab for use in the treatment of hidradenitis suppurativa

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5959087A (en) 1989-08-07 1999-09-28 Peptide Technology, Ltd. Tumour necrosis factor binding ligands
US6448380B2 (en) 1989-08-07 2002-09-10 Peptech Limited Tumor necrosis factor antibodies
CA2065346C (en) 1989-09-05 2005-03-29 Craig A. Smith Tumor necrosis factor-.alpha. and-.beta. receptors
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
DE69233697T2 (de) 1991-03-01 2008-01-24 Dyax Corp., Cambridge Verfahren zur Entwicklung von bindenden Mikroproteinen
US5656272A (en) 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
DE07012626T1 (de) 1991-03-18 2010-01-21 New York University Monoklonale und chimäre Antikörper gegen humanen Tumornekrosefaktor
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
JP3540315B2 (ja) 1991-09-23 2004-07-07 メディカル リサーチ カウンシル キメラ抗体の製造−組合せアプローチ
WO1993019751A1 (en) 1992-04-02 1993-10-14 Smithkline Beecham Corporation Compounds useful for treating inflammatory diseases and inhibiting production of tumor necrosis factor
NZ256293A (en) 1992-09-15 1997-06-24 Immunex Corp Method of treating tumour necrosis factor - mediated inflammation by use of tnf antagonist
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
ATE239041T1 (de) 1996-02-09 2003-05-15 Basf Ag Humane antikörper welche an humanen tnfalpha binden
US6537549B2 (en) 1999-02-24 2003-03-25 Edward L. Tobinick Cytokine antagonists for the treatment of localized disorders
US6177077B1 (en) 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
EP1345968A2 (en) 2000-12-28 2003-09-24 Altus Biologics Inc. Crystals of whole antibodies and fragments thereof and methods for making and using them
BR0206160A (pt) 2001-05-25 2004-10-26 Abbott Gmbh & Co Kg Uso de anticorpos anti-tnf como medicamentos no tratamento de distúrbios sépticos de pacientes anêmicos
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20030161828A1 (en) 2002-02-19 2003-08-28 Abbott Gmbh & Co. Kg Use of TNF antagonists as drugs for the treatment of patients with an inflammatory reaction and without suffering from total organ failure
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20040009172A1 (en) 2002-04-26 2004-01-15 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20090280065A1 (en) 2006-04-10 2009-11-12 Willian Mary K Uses and Compositions for Treatment of Psoriasis
US20040131614A1 (en) 2002-07-19 2004-07-08 Abbott Biotechnology Ltd. Treatment of pulmonary disorders using TNFalpha inhibitor
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
TWI439284B (zh) * 2004-04-09 2014-06-01 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
CN1988918A (zh) * 2004-04-09 2007-06-27 艾博特生物技术有限公司 用于治疗TNFα－相关病症的多变剂量方案
WO2006041970A2 (en) 2004-10-08 2006-04-20 Abbott Biotechnology Ltd. Treatment of respiratory syncytial virus (rsv) infection
JP5757495B2 (ja) 2005-05-16 2015-07-29 アッヴィ バイオテクノロジー リミテッド びらん性多発性関節炎の治療のためのｔｎｆ阻害剤の使用
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
TW201337266A (zh) 2005-11-01 2013-09-16 Abbott Biotech Ltd 利用生物標記診斷關節黏連脊椎炎之方法及組合物
CN102391358B (zh) 2006-04-05 2016-08-10 艾伯维生物技术有限公司 抗体纯化
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US20090317399A1 (en) 2006-04-10 2009-12-24 Pollack Paul F Uses and compositions for treatment of CROHN'S disease
WO2007120626A2 (en) 2006-04-10 2007-10-25 Abbott Biotechnology Ltd. Uses and compositions for treatment of ankylosing spondylitis
WO2008063213A2 (en) 2006-04-10 2008-05-29 Abbott Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
US9399061B2 (en) 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
US20080118496A1 (en) 2006-04-10 2008-05-22 Medich John R Uses and compositions for treatment of juvenile rheumatoid arthritis
US20080131374A1 (en) 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
US20080311043A1 (en) 2006-06-08 2008-12-18 Hoffman Rebecca S Uses and compositions for treatment of psoriatic arthritis
US20100021451A1 (en) 2006-06-08 2010-01-28 Wong Robert L Uses and compositions for treatment of ankylosing spondylitis
CN103316402A (zh) 2006-06-30 2013-09-25 艾伯维生物技术有限公司 自动注射装置
TW201516149A (zh) 2006-09-13 2015-05-01 Abbvie Inc 細胞培養改良
EP2684895A1 (en) 2006-10-27 2014-01-15 AbbVie Biotechnology Ltd Crystalline anti-hTNFalpha antibodies
EP2165194A4 (en) 2007-05-31 2010-09-08 Abbott Lab BIOMARKERS FOR PREDICTING RESPONSABILITY TO TNF ALPHA INHIBITORS IN AUTOIMMUNE DISEASES
WO2008150490A2 (en) 2007-06-01 2008-12-11 Abbott Biotechnology Ltd. Uses and compositions for treatment of psoriasis and crohn's disease
EP2171451A4 (en) 2007-06-11 2011-12-07 Abbott Biotech Ltd METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS
CA2693771A1 (en) 2007-07-13 2009-01-22 Abbott Biotechnology Ltd. Methods and compositions for pulmonary administration of a tnf.alpha. inhibitor
MX2010001488A (es) 2007-08-08 2010-03-01 Abbott Lab Composiciones y metodos para cristalizar anticuerpos.
WO2009032128A1 (en) 2007-08-28 2009-03-12 Abbott Biotechnology Ltd. Compositions and methods comprising binding proteins for adalimumab
US8420081B2 (en) 2007-11-30 2013-04-16 Abbvie, Inc. Antibody formulations and methods of making same
EP2225276B1 (en) * 2007-12-31 2014-04-23 Bayer Intellectual Property GmbH Antibodies to tnf alpha
MX2010007393A (es) 2008-01-03 2010-11-09 Abbott Biotech Ltd Anticipacion de eficacia a largo plazo de un compuesto en el tratamiento de psoriasis.
SG2013054218A (en) 2008-01-15 2014-10-30 Abbott Gmbh & Co Kg Powdered protein compositions and methods of making same
ES2579231T3 (es) 2008-01-15 2016-08-08 Abbvie Inc Vectores de expresión de mamíferos mejorados y usos de los mismos
MX2010010503A (es) 2008-03-24 2010-11-09 Abbott Biotech Ltd Metodos y composiciones para tratar perdida osea.
CN101684156B (zh) * 2008-09-27 2011-12-28 苏州工业园区晨健抗体组药物开发有限公司 人TNFα单克隆抗体、其PEG化纳米颗粒及其应用
AU2010242972B2 (en) 2009-04-29 2015-07-09 Abbvie Biotechnology Ltd Automatic injection device
US20100278822A1 (en) 2009-05-04 2010-11-04 Abbott Biotechnology, Ltd. Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione
JP2013518590A (ja) 2010-02-02 2013-05-23 アボツト・バイオテクノロジー・リミテツド ＴＮＦ−α阻害剤を用いる処置に対する応答性を予測するための方法および組成物
MX2012014080A (es) * 2010-06-03 2013-05-01 Abbvie Biotechnology Ltd Usos y composiciones para el tratamiento de hidradenitis superativa (hs).

Also Published As

Publication number Publication date
CN105056232A (zh) 2015-11-18
CN103079594A (zh) 2013-05-01
CA2801917A1 (en) 2011-12-08
JP2013533858A (ja) 2013-08-29
CN103079594B (zh) 2016-04-13
US20170101465A1 (en) 2017-04-13
SMT201800428T1 (it) 2018-09-13
DK2575884T3 (en) 2018-09-03
PT2575884T (pt) 2018-10-31
WO2011153477A2 (en) 2011-12-08
CY1120664T1 (el) 2019-12-11
EP2575884A2 (en) 2013-04-10
US8747854B2 (en) 2014-06-10
JP5944382B2 (ja) 2016-07-05
US20150147335A1 (en) 2015-05-28
US9334320B2 (en) 2016-05-10
MX2012014080A (es) 2013-05-01
EP2575884A4 (en) 2013-12-04
HUE039740T2 (hu) 2019-01-28
RS57543B1 (sr) 2018-10-31
WO2011153477A3 (en) 2012-03-15
US20110300151A1 (en) 2011-12-08
CA2801917C (en) 2017-04-25
HRP20181598T1 (hr) 2018-11-30
JP2016193916A (ja) 2016-11-17
PL2575884T3 (pl) 2018-12-31
ES2685607T3 (es) 2018-10-10
EP2575884B1 (en) 2018-07-18
LT2575884T (lt) 2018-09-25

Similar Documents

Publication Publication Date Title
SMT201800428T1 (it) Usi e composizioni per il trattamento della idrosadenite suppurativa (hs)
IL254909A0 (en) Preparations and methods for treating edible material and their substrates
ZA201208642B (en) Treatment of modified atmosphere packaging
EP2640782A4 (en) Compositions and articles of manufacture containing siloxane
IL223153A0 (en) Compositions comprising acid and derivatives thereof and uses thereof
ZA201208413B (en) Skin treatment composition
GB201302653D0 (en) Pharmaceutical compositions and methods of treatment
GB0902040D0 (en) Composition for treatment of skin
PH12014500667A1 (en) Compositions for skin exfoliation and use thereof
IL225793A0 (en) Methods and preparations for curing insulin-related medical conditions
HUE038787T2 (hu) Tripeptid készítmények és alkalmazásuk diabétesz kezelésére
IL223289A0 (en) Treatment of type 2 diabetes
HUE038907T2 (hu) Étrendi zsír felszívódásának csökkentésére szolgáló készítmény
ZA201301936B (en) Methods and compositions for treatment of diabetes and dyslipidemia
SI2632475T1 (sl) Sestavki za zdravljenje perifernih ulkusov različnih izvorov
EP2659879A4 (en) HAIR TREATMENT AGENT COMPOSITION
ZA201304353B (en) Remedial composition and treatment methods
EP2612654A4 (en) COSMETIC COMPOSITION FOR IMPROVING THE ELASTICITY OF THE SKIN
ZA201208568B (en) Skin treatment composition
HK1183810A (en) Uses and compositions for treatment of hidradenitis suppurativa (hs)
EP2649096A4 (en) HEMOGLOBIN COMPOSITIONS AND METHODS OF USE
PT2453912T (pt) Composição para tratamento de leishmaníase canina e humana
GB201010638D0 (en) Composition for treatment of skin
IL226347A0 (en) Formulation of an influential factor
PL2456445T3 (pl) Środek do leczenia chorób skóry